Andexanet alfa (Andexxa) made its quiet exit from the U.S. market just a few weeks ago. It's an interesting story so in case you missed it, I'll recap what andexanet alfa is, or rather was, and what happened that led to its removal. Being pulled from the U.S. market may have come to a surprise for some considering its main study (ANNEXA-I) was stopped early for successfully meeting its main efficacy outcome. While having a trial stopped early for superior efficacy results sounds good on the surface, it can have negative ramifications on other aspects of the clinical inquiry (explained below).
